We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$740M
AUM Growth
-$43.3M
Cap. Flow
-$86.3M
Cap. Flow %
-11.66%
Top 10 Hldgs %
29.49%
Holding
104
New
10
Increased
27
Reduced
49
Closed
9

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.8M
2
GILD icon
Gilead Sciences
GILD
+$9.89M
3
COR icon
Cencora
COR
+$7.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.72M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$6.41M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$20.2M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.8M
3
ABMD
Abiomed Inc
ABMD
+$10M
4
AET
Aetna Inc
AET
+$9.86M
5
CVS icon
CVS Health
CVS
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 90.07%
2 Financials 0.19%
3 Technology 0.17%
4 Energy 0.14%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
101
DELISTED
Radius Health, Inc.
RDUS
– –
-90,000
Closed -$3.47M
AET
102
DELISTED
Aetna Inc
AET
– –
-62,000
Closed -$9.86M
BIVV
103
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-35,000
Closed -$2M
1 2 3 4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rhenman & Partners Asset Management held 104 positions worth $740M, down 5.5% from $783M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $86.3M in Q4 2017, closing 9 positions and reducing 49 holdings. Its most notable exit was Aetna Inc, an estimated $9.86M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Acadia Pharmaceuticals worth $10.2M.

  • Rhenman & Partners Asset Management's largest Q4 2017 buy was Acadia Pharmaceuticals: 338,882 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2017, an estimated $9.89M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $20.2M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2017, selling an estimated $9.86M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $740M portfolio in Q4 2017.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 9 in Q4 2017.
  • Rhenman & Partners Asset Management's portfolio value fell 5.5% quarter-over-quarter to $740M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2017, filed 19 Jan 2018.